Tectonic Therapeutic Inc (TECX)
NASDAQ:TECX
Want to see TECX full AI Analyst Report?
Top Page
Tectonic Therapeutic
(NASDAQ:TECX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$29.00
▼(-1.73% Downside)
Action:Reiterated
Date:06/11/26
The score is driven primarily by mixed financial performance: a strong low-debt balance sheet is offset by pre-revenue status, accelerating losses, and significant ongoing cash burn. Technical indicators are broadly neutral, while valuation support is limited due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage / Balance Sheet Strength
Tectonic carries very low leverage with minimal debt versus a sizable equity and asset base, providing durable financial flexibility. This reduces near-term solvency risk and supports funding clinical programs or strategic deals without immediate distress financing, preserving optionality.
Negative Factors
Pre-revenue Business Model
Tectonic remains pre-revenue, meaning its long-term value depends entirely on successful development and commercialization of pipeline candidates. Without product revenues, the company must continually finance operations, leaving future cash flows uncertain until commercial milestones are achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
Tectonic carries very low leverage with minimal debt versus a sizable equity and asset base, providing durable financial flexibility. This reduces near-term solvency risk and supports funding clinical programs or strategic deals without immediate distress financing, preserving optionality.
Read all positive factors
Tectonic Therapeutic (TECX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$553.62M
Dividend YieldN/A
Average Volume (3M)212.28K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth38.99%
CountryUS
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.46
Shares Outstanding18,869,186
10 Day Avg. Volume162,551
30 Day Avg. Volume212,280
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$80.75Price Target Upside173.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.34
Revenue Forecast (FY)N/A
Tectonic Therapeutic Business Overview & Revenue Model
Company Description
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled recept...
How the Company Makes Money
null...
Tectonic Therapeutic Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -81.17M | -71.48M | -56.23M | -41.19M | -31.03M | -8.12M |
| Net Income | -83.49M | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
Balance Sheet | ||||||
| Total Assets | 246.58M | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M |
| Cash, Cash Equivalents and Short-Term Investments | 236.89M | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M |
| Total Debt | 4.63M | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Total Liabilities | 16.16M | 9.71M | 12.13M | 124.03M | 92.86M | 47.84M |
| Stockholders Equity | 230.42M | 251.33M | 140.78M | -84.64M | -45.65M | -14.96M |
Cash Flow | ||||||
| Free Cash Flow | -65.66M | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M |
| Operating Cash Flow | -65.41M | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M |
| Investing Cash Flow | -102.00K | -138.00K | -156.00K | -279.00K | -267.00K | -2.12M |
| Financing Cash Flow | -3.92M | 173.35M | 171.71M | 33.75M | 262.00K | 41.42M |
Tectonic Therapeutic Technical Analysis
Negative
29.51
Price Trends
29.02
Negative
27.18
Positive
22.89
Positive
Market Momentum
-0.04
Positive
46.23
Neutral
32.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Negative. The current price of 29.51 is above the 20-day moving average (MA) of 28.90, above the 50-day MA of 29.02, and above the 200-day MA of 22.89, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.23 is Neutral, neither overbought nor oversold. The STOCH value of 32.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECX.
Tectonic Therapeutic Risk Analysis
Tectonic Therapeutic disclosed 77 risk factors in its most recent earnings report. Tectonic Therapeutic reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tectonic Therapeutic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $315.18M | 4.73 | 41.40% | ― | ― | ― | |
57 Neutral | $736.78M | 8.50 | -54.39% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $553.62M | -6.60 | -32.33% | ― | ― | 38.99% | |
47 Neutral | $329.79M | -3.90 | -47.48% | ― | ― | 56.00% | |
46 Neutral | $49.77M | -1.40 | -81.25% | ― | ― | 28.17% | |
46 Neutral | $238.38M | -3.75 | 85.78% | ― | 20.08% | 14.06% |
* Healthcare Sector Average
TECX
Tectonic Therapeutic
29.34
6.90
30.75%
OMER
Omeros
10.18
6.63
186.76%
ABEO
Abeona Therapeutics
5.53
-0.71
-11.45%
MREO
Mereo Biopharma Group Plc
0.31
-2.47
-88.81%
FHTX
Foghorn Therapeutics
4.06
-0.48
-10.57%
LXEO
Lexeo Therapeutics, Inc.
4.20
0.11
2.69%
Tectonic Therapeutic Corporate Events
Business Operations and StrategyExecutive/Board ChangesProduct-Related AnnouncementsShareholder Meetings
Tectonic Therapeutic Completes Enrollment in Key TX45 Trial
Positive
Jun 10, 2026
On June 8, 2026, Tectonic Therapeutic, Inc. held its 2026 annual stockholders’ meeting, where shareholders elected Timothy A. Springer and Stefan Vitorovic as Class II directors to serve until the 2029 meeting. Investors also ratified Deloit...
Business Operations and StrategyExecutive/Board Changes
Tectonic Therapeutic Adds Veteran Banker to Board
Positive
Apr 23, 2026
On April 23, 2026, Tectonic Therapeutic announced the appointment of veteran healthcare investment banker Jessica Chutter to its Board of Directors and Audit Committee, effective June 8, 2026, with her term as a Class III director running until th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.